Bicycle Therapeutics (NASDAQ: BCYC) outlines 2026 strategic priorities

Rhea-AI Filing Summary

Bicycle Therapeutics plc filed a current report to share that it issued a press release on January 12, 2026 describing its recent accomplishments and strategic priorities for 2026. The company furnished this press release as Exhibit 99.1 to the report.

The filing confirms that Bicycle Therapeutics’ American Depositary Shares trade on The Nasdaq Stock Market under the symbol BCYC, and it includes standard exhibit and signature information, with the report signed by the company’s Chief Financial Officer, Alethia Young.

false 0001761612 X0 00-0000000 true 0001761612 2026-01-12 2026-01-12 0001761612 us-gaap:CommonStockMember 2026-01-12 2026-01-12 0001761612 bcyc:AmericanDepositarySharesMember 2026-01-12 2026-01-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

January 12, 2026

Date of Report (Date of earliest event reported)

Bicycle Therapeutics plc

(Exact name of registrant as specified in its charter)

England and Wales		001-38916		Not applicable
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

Blocks A & B, Portway Building, Granta Park Great Abington, Cambridge United Kingdom	CB21 6GS
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: +44 1223 261503

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol (s)	Name of each exchange on which registered
Ordinary shares, nominal value £0.01 per share	n/a	The Nasdaq Stock Market LLC*
American Depositary Shares, each representing one ordinary share, nominal value £0.01 per share	BCYC	The Nasdaq Stock Market LLC

* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). 

Emerging growth company  ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01. Other Events

On January 12, 2026, Bicycle Therapeutics plc (the “Company”) issued a press release announcing the Company’s recent accomplishments and outlining strategic priorities for 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 8.01 by reference.

Item 9.01 Financial Statements and Exhibits

(d)       Exhibits

Exhibit No.		Description
99.1		Press Release issued January 12, 2026
104		Cover Page Interactive Data File (formatted in Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 12, 2026	BICYCLE THERAPEUTICS PLC
	By:	/s/ Alethia Young
	Name: Alethia Young
	Title: Chief Financial Officer

FAQ

What did Bicycle Therapeutics plc (BCYC) report in this 8-K filing?

Bicycle Therapeutics plc reported that on January 12, 2026 it issued a press release highlighting the company’s recent accomplishments and outlining its strategic priorities for 2026, which is furnished as Exhibit 99.1.

When did Bicycle Therapeutics issue the press release mentioned in the 8-K?

Bicycle Therapeutics issued the press release on January 12, 2026, the same date identified as the earliest event reported in the current report.

Where can investors find the full details of Bicycle Therapeutics’ 2026 strategic priorities?

Full details are contained in the press release attached to the report as Exhibit 99.1, which is incorporated by reference into Item 8.01 of the filing.

On which exchange are Bicycle Therapeutics’ shares traded and under what symbol?

Bicycle Therapeutics’ American Depositary Shares, each representing one ordinary share with a nominal value of £0.01, are listed on The Nasdaq Stock Market LLC under the trading symbol BCYC.

Who signed the Bicycle Therapeutics 8-K related to the 2026 strategic priorities update?

The report was signed on behalf of Bicycle Therapeutics plc by Alethia Young, who is identified as the company’s Chief Financial Officer.

What exhibits were included with Bicycle Therapeutics’ January 12, 2026 8-K filing?

The filing includes Exhibit 99.1, the press release issued January 12, 2026, and Exhibit 104, the cover page interactive data file formatted in Inline XBRL.